Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01180946 · ClinicalTrials.gov registry record · NA
Vitamin D Deficiency in Adolescent Girls
A NA study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- NA
- Development phase
- 90
- Enrollment target
NCT01180946: Completed NA study, sponsored by Massachusetts General Hospital.
NCT01180946 is a NA study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 90 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01180946, a NA study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- NA
- Development phase
- 90 participants
- Enrollment target
Study Summary
Fibroblast growth factor 23 (FGF23) is a newly discovered hormone which regulates phosphate and vitamin D levels. In this study, we are looking at what the normal levels of FGF23 are in adolescent girls and how these levels vary with other hormonal measurements. We will also be looking at whether vitamin D supplementation in adolescents who are deficient in vitamin D alters the levels of FGF23 and other factors including insulin resistance.
Interventions
- OTHER placebo pill
- DIETARY_SUPPLEMENT ergocalciferol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2010-09 |
| Est. Completion | 2013-04 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01180946
The ClinicalTrials.gov registry entry for NCT01180946 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo pill is the first listed.
NCT01180946 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01180946 about?
NCT01180946 is a clinical study titled "Vitamin D Deficiency in Adolescent Girls". Fibroblast growth factor 23 (FGF23) is a newly discovered hormone which regulates phosphate and vitamin D levels. In this study, we are looking at what the normal levels of FGF23 are in adolescent girls and how these levels vary with other hormonal measurements. We will also be looking at whether vi...
What is the current status of trial NCT01180946?
This trial is currently completed. It is a NA study. The enrollment target is 90 participants. The study started on 2010-09. Estimated completion is 2013-04.
What interventions are being tested in trial NCT01180946?
The interventions under investigation include: placebo pill (OTHER), ergocalciferol (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT01180946?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.